Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca
The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of …
Real-time market intelligence across asset classes
Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.
AI-curated news influencing IBB price, sentiment, and trend
The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of …
It notched convincing beats on analyst estimates with its second-quarter performance.
Specialist funds returned nearly 40% as AI drug discovery and deal activity attracted additional capital.
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the …
Latigo Biotherapeutics Inc. filed for an initial public offering, joining a growing list of biotechnology firms considering going public as …
Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.
Multi-Provider AI Analysis